Table 1.
Some representative completed and ongoing clinical trials exploiting LVs in cancer therapy.
| Conditions | Interventions | Locations | Phase | Identifier |
|---|---|---|---|---|
| Hematopoietic/Lymphoid cancer and 22 more malignancies | CART-19 | Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States | Phase 1 | NCT01029366 |
| B-cell non-Hodgkin lymphoma | CART-19 | Peking Union Medical College Hospital, Beijing, China | Phase 1 | NCT03483688 |
| Lymphoma | rHIV7-shI-TAR-CCR5RZ LV-transduced HPCs + carmustine + cyclophosphamide + etoposide | City of Hope Medical Center, Duarte, California, United States | Phase 1 | NCT00569985 |
| Advanced solid tumor | TCRT-ESO-A2 | Baylor University Medical Cancer Hospital, Dallas, Texas, United States | Phase 1 | NCT04878484 |
| Hematologic malignancy and 4 more malignancies | cCARTs cells | The General Hospital of Western Theater Command, Chengdu, China; Peking University Shenzhen Hospital, Shenzhen, China | Early Phase 1 | NCT03795779 |
| Metastatic breast cancer | huMNC2-CAR44 CARTs | City of Hope Medical Center, Duarte, California, United States | Phase 1 | NCT04020575 |
| Malignant neoplasm of nasopharynx and breast cancer recurrent | CAR-T cells recognizing EpCAM | West China Hospital, Sichuan University, Chengdu, Sichuan, China | Phase 1 | NCT02915445 |
| Hepatocellular carcinoma and metastatic liver cancer | ECT204 T cells | City of Hope, Duarte, California, United States Kansas University Cancer Center, Westwood, Kansas, United States |
Phase 1/2 | NCT04864054 |
| Glioblastoma multiforme | Interferon-α2-modified HSPCs + temferon | Ospedale San Raffaele, Milan, Italy Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milan, Italy Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy |
Phase 1/2 | NCT03866109 |
| Multiple myeloma | bb2121 | Mayo Clinic Arizona Scottsdale, Arizona, United States UCSF Medical Center, San Francisco, California, United States Moffitt Cancer Center, Tampa, Florida, United States and 24 more centers |
Phase 2 | NCT03601078 |
| Relapsed/Refractory B-cell Lymphoma, Childhood | CART-19 | Children's Hospital of Fudan University, Shanghai, China | Phase 1/2 | NCT03265106 |
| BPDCN | MB-102 + Fludarabine + Cyclophosphamide | City of Hope Medical Center, Duarte, California, United States Dana-Farber Cancer Institute, Boston, Massachusetts, United States Duke University, Durham, North Carolina, United States MD Anderson Cancer Center, Houston, Texas, United States |
Phase 1/2 | NCT04109482 |
| Relapsed or refractory B-ALL | CART-19 | Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States | Phase 2 | NCT02030847 |
| Recurrent ALL and CLL | Autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes | Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States | Phase 1/2 | NCT01865617 |
| Multiple Myeloma | JNJ-68284528 | Mayo Clinic Cancer Center–Scottsdale, Phoenix, Arizona, United States and 20 more centers | Phase 1/2 | NCT03548207 |